BRAF and MEK inhibitors (BRAF/MEKi) favor melanoma-infiltrating lymphocytes, providing the rationale for current combinatorial trials with anti-PD1 antibody. A portion of melanoma cells may express PD1, and anti-PD1 antibody could have a direct anti-tumor effect. Here, we explore if BRAF/MEKi modulate rates of PD1+ melanoma cells, supporting an additional - lymphocyte-independent - basis for their therapeutic combination with anti-PD1 antibody.
Titolo: | BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody |
Autori Riconosciuti: | |
Autori: | Sanlorenzo, Martina; Vujic, Igor; Floris, Arianna; Novelli, Mauro; Gammaitoni, Loretta; Giraudo, Lidia; Macagno, Marco; Leuci, Valeria; Rotolo, Ramona; Donini, Chiara; Basiricò, Marco; Quaglino, Pietro; Fierro, Maria Teresa; Giordano, Silvia; Sibilia, Maria; Carnevale-Schianca, Fabrizio; Aglietta, Massimo; Sangiolo, Dario |
Data di pubblicazione: | 2018 |
Abstract: | BRAF and MEK inhibitors (BRAF/MEKi) favor melanoma-infiltrating lymphocytes, providing the rationale for current combinatorial trials with anti-PD1 antibody. A portion of melanoma cells may express PD1, and anti-PD1 antibody could have a direct anti-tumor effect. Here, we explore if BRAF/MEKi modulate rates of PD1+ melanoma cells, supporting an additional - lymphocyte-independent - basis for their therapeutic combination with anti-PD1 antibody. |
Volume: | 24 |
Fascicolo: | 14 |
Pagina iniziale: | 3377 |
Pagina finale: | 3385 |
Digital Object Identifier (DOI): | 10.1158/1078-0432.CCR-17-1914 |
Parole Chiave: | BRAF, MEK inhibitors, PD1-positive, melanoma,lymphocyte-independent, synergism,anti-PD1, antibody |
Rivista: | CLINICAL CANCER RESEARCH |
Appare nelle tipologie: | 03A-Articolo su Rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
1078-0432.CCR-17-1914.full.pdf | POSTPRINT (VERSIONE FINALE DELL’AUTORE) | Open Access Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.